{"id":"https://openalex.org/W2090149045","doi":"https://doi.org/10.1517/14728220802517935","title":"Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues","display_name":"Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues","publication_year":2008,"publication_date":"2008-11-06","ids":{"openalex":"https://openalex.org/W2090149045","doi":"https://doi.org/10.1517/14728220802517935","mag":"2090149045","pmid":"https://pubmed.ncbi.nlm.nih.gov/18990083"},"language":"en","primary_location":{"id":"doi:10.1517/14728220802517935","doi":"https://doi.org/10.1517/14728220802517935","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14728220802517935","pdf_url":null,"source":{"id":"https://openalex.org/S57380513","display_name":"Expert Opinion on Biological Therapy","issn_l":"1471-2598","issn":["1471-2598","1744-7682"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Biological Therapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5030465858","display_name":"Emilio Bria","orcid":"https://orcid.org/0000-0002-2333-704X","observed_orcids":["https://orcid.org/0000-0002-2333-704X"]},"institutions":[{"id":"https://openalex.org/I4387152244","display_name":"Instituto Nazionale Tumori Regina Elena","ror":"https://ror.org/04mgfev69","country_code":"IT","type":"facility","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4387152244"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Emilio Bria","raw_affiliation_strings":["Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy. emiliobria@yahoo.it","+39 06 526 6219","Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy. emiliobria@yahoo.it","institution_ids":["https://openalex.org/I4387152244"]},{"raw_affiliation_string":"+39 06 526 6219","institution_ids":[]},{"raw_affiliation_string":"Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132","institution_ids":["https://openalex.org/I4387152244"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073656652","display_name":"Federica Cuppone","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152244","display_name":"Instituto Nazionale Tumori Regina Elena","ror":"https://ror.org/04mgfev69","country_code":"IT","type":"facility","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4387152244"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Federica Cuppone","raw_affiliation_strings":["Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132; +39 06 526 6219; emiliobria@yahoo.it","+39 06 526 6219","Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132; +39 06 526 6219; emiliobria@yahoo.it","institution_ids":["https://openalex.org/I4387152244"]},{"raw_affiliation_string":"+39 06 526 6219","institution_ids":[]},{"raw_affiliation_string":"Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132","institution_ids":["https://openalex.org/I4387152244"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023848359","display_name":"Mich\u00e8le Milella","orcid":"https://orcid.org/0000-0002-3826-5237","observed_orcids":["https://orcid.org/0000-0002-3826-5237"]},"institutions":[{"id":"https://openalex.org/I4387152244","display_name":"Instituto Nazionale Tumori Regina Elena","ror":"https://ror.org/04mgfev69","country_code":"IT","type":"facility","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4387152244"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Michele Milella","raw_affiliation_strings":["Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132; +39 06 526 6219; emiliobria@yahoo.it","+39 06 526 6219","Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132; +39 06 526 6219; emiliobria@yahoo.it","institution_ids":["https://openalex.org/I4387152244"]},{"raw_affiliation_string":"+39 06 526 6219","institution_ids":[]},{"raw_affiliation_string":"Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132","institution_ids":["https://openalex.org/I4387152244"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109231846","display_name":"Sunil Verma","orcid":"https://orcid.org/0009-0005-1382-4978","observed_orcids":["https://orcid.org/0009-0005-1382-4978"]},"institutions":[{"id":"https://openalex.org/I1323843004","display_name":"Sunnybrook Health Science Centre","ror":"https://ror.org/03wefcv03","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1323843004"]},{"id":"https://openalex.org/I185261750","display_name":"University of Toronto","ror":"https://ror.org/03dbr7087","country_code":"CA","type":"education","lineage":["https://openalex.org/I185261750"]},{"id":"https://openalex.org/I4405271711","display_name":"Odette Cancer Centre","ror":"https://ror.org/02ww1s787","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1323843004","https://openalex.org/I4405271711"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Sunil Verma","raw_affiliation_strings":["University of Toronto, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Toronto, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada","institution_ids":["https://openalex.org/I1323843004","https://openalex.org/I185261750","https://openalex.org/I4405271711"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020732852","display_name":"Paolo Carlini","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152244","display_name":"Instituto Nazionale Tumori Regina Elena","ror":"https://ror.org/04mgfev69","country_code":"IT","type":"facility","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4387152244"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Paolo Carlini","raw_affiliation_strings":["Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132; +39 06 526 6219; emiliobria@yahoo.it","+39 06 526 6219","Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132; +39 06 526 6219; emiliobria@yahoo.it","institution_ids":["https://openalex.org/I4387152244"]},{"raw_affiliation_string":"+39 06 526 6219","institution_ids":[]},{"raw_affiliation_string":"Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132","institution_ids":["https://openalex.org/I4387152244"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039867262","display_name":"Cecilia Nistic\u00f2","orcid":"https://orcid.org/0000-0002-2379-5550","observed_orcids":["https://orcid.org/0000-0002-2379-5550"]},"institutions":[{"id":"https://openalex.org/I4387152244","display_name":"Instituto Nazionale Tumori Regina Elena","ror":"https://ror.org/04mgfev69","country_code":"IT","type":"facility","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4387152244"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Cecilia Nistic\u00f2","raw_affiliation_strings":["Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132; +39 06 526 6219; emiliobria@yahoo.it","+39 06 526 6219","Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132; +39 06 526 6219; emiliobria@yahoo.it","institution_ids":["https://openalex.org/I4387152244"]},{"raw_affiliation_string":"+39 06 526 6219","institution_ids":[]},{"raw_affiliation_string":"Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132","institution_ids":["https://openalex.org/I4387152244"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111493709","display_name":"Vanja Vaccaro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152244","display_name":"Instituto Nazionale Tumori Regina Elena","ror":"https://ror.org/04mgfev69","country_code":"IT","type":"facility","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4387152244"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Vanja Vaccaro","raw_affiliation_strings":["Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132; +39 06 526 6219; emiliobria@yahoo.it","+39 06 526 6219","Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132; +39 06 526 6219; emiliobria@yahoo.it","institution_ids":["https://openalex.org/I4387152244"]},{"raw_affiliation_string":"+39 06 526 6219","institution_ids":[]},{"raw_affiliation_string":"Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132","institution_ids":["https://openalex.org/I4387152244"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032078755","display_name":"Ant\u00f4nio Rossi","orcid":"https://orcid.org/0000-0003-3295-0345","observed_orcids":["https://orcid.org/0000-0003-3295-0345"]},"institutions":[{"id":"https://openalex.org/I4210111929","display_name":"Azienda Ospedaliera S.Giuseppe Moscati","ror":"https://ror.org/021jxzw96","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210111929"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Antonio Rossi","raw_affiliation_strings":["SG Moscati Hospital, Division of Medical Oncology, Avellino, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"SG Moscati Hospital, Division of Medical Oncology, Avellino, Italy","institution_ids":["https://openalex.org/I4210111929"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059367989","display_name":"Giuseppe Tonini","orcid":"https://orcid.org/0000-0003-4442-8677","observed_orcids":["https://orcid.org/0000-0003-4442-8677"]},"institutions":[{"id":"https://openalex.org/I155125353","display_name":"Universit\u00e0 Campus Bio-Medico","ror":"https://ror.org/04gqx4x78","country_code":"IT","type":"education","lineage":["https://openalex.org/I155125353"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Giuseppe Tonini","raw_affiliation_strings":["University Campus Bio-Medico, Department of Medical Oncology, Rome, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Campus Bio-Medico, Department of Medical Oncology, Rome, Italy","institution_ids":["https://openalex.org/I155125353"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052556729","display_name":"Francesco Cognetti","orcid":"https://orcid.org/0000-0003-2022-9446","observed_orcids":["https://orcid.org/0000-0003-2022-9446"]},"institutions":[{"id":"https://openalex.org/I4387152244","display_name":"Instituto Nazionale Tumori Regina Elena","ror":"https://ror.org/04mgfev69","country_code":"IT","type":"facility","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4387152244"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Francesco Cognetti","raw_affiliation_strings":["Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132; +39 06 526 6219; emiliobria@yahoo.it","+39 06 526 6219","Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132; +39 06 526 6219; emiliobria@yahoo.it","institution_ids":["https://openalex.org/I4387152244"]},{"raw_affiliation_string":"+39 06 526 6219","institution_ids":[]},{"raw_affiliation_string":"Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132","institution_ids":["https://openalex.org/I4387152244"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5025381371","display_name":"Edmondo Terzoli","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152244","display_name":"Instituto Nazionale Tumori Regina Elena","ror":"https://ror.org/04mgfev69","country_code":"IT","type":"facility","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4387152244"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Edmondo Terzoli","raw_affiliation_strings":["Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132; +39 06 526 6219; emiliobria@yahoo.it","+39 06 526 6219","Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132; +39 06 526 6219; emiliobria@yahoo.it","institution_ids":["https://openalex.org/I4387152244"]},{"raw_affiliation_string":"+39 06 526 6219","institution_ids":[]},{"raw_affiliation_string":"Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy +39 065 266 6132","institution_ids":["https://openalex.org/I4387152244"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.5897,"has_fulltext":false,"cited_by_count":36,"citation_normalized_percentile":{"value":0.89733438,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"8","issue":"12","first_page":"1963","last_page":"1971"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11535","display_name":"Chemotherapy-induced cardiotoxicity and mitigation","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11535","display_name":"Chemotherapy-induced cardiotoxicity and mitigation","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.996999979019165},{"id":"https://openalex.org/keywords/cardiotoxicity","display_name":"cardiotoxicity","score":0.9860000014305115},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9570000171661377},{"id":"https://openalex.org/keywords/cardiomyocyte-injury","display_name":"cardiomyocyte injury","score":0.9010000228881836},{"id":"https://openalex.org/keywords/cardiac-dysfunction","display_name":"cardiac dysfunction","score":0.8730000257492065},{"id":"https://openalex.org/keywords/adjuvant-therapy","display_name":"adjuvant therapy","score":0.8259999752044678}],"concepts":[{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.9716079235076904},{"id":"https://openalex.org/C2778233292","wikidata":"https://www.wikidata.org/wiki/Q2118956","display_name":"Cardiotoxicity","level":3,"score":0.9124785661697388},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8265680074691772},{"id":"https://openalex.org/C2776802502","wikidata":"https://www.wikidata.org/wiki/Q417589","display_name":"Anthracycline","level":4,"score":0.6543785333633423},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5864916443824768},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5461261868476868},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5289078950881958},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.5247982740402222},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.49150264263153076},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.4763108491897583},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.4617583453655243},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.44507184624671936},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.42729076743125916},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3364025950431824}],"mesh":[{"descriptor_ui":"D000068878","descriptor_name":"Trastuzumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006321","descriptor_name":"Heart","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1517/14728220802517935","doi":"https://doi.org/10.1517/14728220802517935","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14728220802517935","pdf_url":null,"source":{"id":"https://openalex.org/S57380513","display_name":"Expert Opinion on Biological Therapy","issn_l":"1471-2598","issn":["1471-2598","1744-7682"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Biological Therapy","raw_type":"journal-article"},{"id":"pmid:18990083","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18990083","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on biological therapy","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":48,"referenced_works":["https://openalex.org/W1520023565","https://openalex.org/W1531524380","https://openalex.org/W1804903119","https://openalex.org/W1912896705","https://openalex.org/W1964321121","https://openalex.org/W1964641698","https://openalex.org/W1969345980","https://openalex.org/W1979563875","https://openalex.org/W1980141913","https://openalex.org/W1983530651","https://openalex.org/W1992234802","https://openalex.org/W1994633980","https://openalex.org/W1998028009","https://openalex.org/W2017772894","https://openalex.org/W2022160610","https://openalex.org/W2029542561","https://openalex.org/W2043103956","https://openalex.org/W2045324973","https://openalex.org/W2048142144","https://openalex.org/W2050674912","https://openalex.org/W2059411043","https://openalex.org/W2081082908","https://openalex.org/W2088255940","https://openalex.org/W2093049418","https://openalex.org/W2103019840","https://openalex.org/W2104337757","https://openalex.org/W2107426197","https://openalex.org/W2110444464","https://openalex.org/W2114880160","https://openalex.org/W2115759102","https://openalex.org/W2117737092","https://openalex.org/W2132278342","https://openalex.org/W2133105825","https://openalex.org/W2136364901","https://openalex.org/W2141469083","https://openalex.org/W2143738177","https://openalex.org/W2144124503","https://openalex.org/W2146384083","https://openalex.org/W2149908785","https://openalex.org/W2152647863","https://openalex.org/W2159459001","https://openalex.org/W2166666753","https://openalex.org/W2249086985","https://openalex.org/W2318605753","https://openalex.org/W2401809930","https://openalex.org/W2418284759","https://openalex.org/W2434504750","https://openalex.org/W4255088724"],"related_works":["https://openalex.org/W4241010313","https://openalex.org/W2771620563","https://openalex.org/W2029059005","https://openalex.org/W275107321","https://openalex.org/W6925176795","https://openalex.org/W2021793782","https://openalex.org/W2528999955","https://openalex.org/W2030893402","https://openalex.org/W2111504321","https://openalex.org/W2081082908"],"abstract_inverted_index":{"BACKGROUND:":[0],"Trastuzumab":[1,179],"has":[2,22,57,82,160],"significantly":[3],"improved":[4],"the":[5,12,50,61,88,91,103,121,133,176,199,207,214,223],"prognosis":[6],"of":[7,53,75,94,123,136,157,167,198,209],"breast":[8],"cancer":[9],"patients":[10,232],"overexpressing":[11],"human":[13],"epidermal":[14],"growth":[15],"factor":[16],"receptor":[17],"2":[18],"(HER2).":[19],"This":[20,159],"result":[21],"been":[23,58,84],"achieved":[24],"in":[25,33,45,60,101,211,222,230],"all":[26],"disease":[27,38],"settings,":[28],"by":[29,40,64],"increasing":[30,41,65],"overall":[31,69],"survival":[32,67,70],"early":[34],"stage":[35],"and":[36,39,68,78,110,142,153],"advanced":[37],"pathological":[42],"complete":[43],"responses":[44],"neoadjuvant":[46],"disease.":[47],"OBJECTIVE:":[48],"Although":[49],"greatest":[51],"impact":[52],"this":[54,137],"monoclonal":[55],"antibody":[56],"seen":[59],"adjuvant":[62,224],"setting,":[63],"disease-free":[66],"rates":[71],"an":[72],"increased":[73,227],"rate":[74],"both":[76,108,140],"symptomatic":[77],"non-symptomatic":[79],"cardiac":[80,96,125,228],"toxicity":[81,97,229],"also":[83],"observed.":[85],"METHODS:":[86],"In":[87],"following":[89],"review,":[90],"different":[92,174],"mechanisms":[93],"trastuzumab":[95,147,210],"are":[98],"described":[99],"and,":[100],"addition,":[102],"clinical":[104,143,220],"data":[105,144,218],"coming":[106],"from":[107,155,175,219],"trials":[109,221],"meta-analyses":[111],"is":[112,117,128],"discussed.":[113],"RESULTS:":[114],"While":[115],"there":[116,127],"strong":[118],"evidence":[119],"for":[120],"incidence":[122],"trastuzumab-related":[124],"toxicity,":[126],"still":[129],"little":[130],"known":[131],"on":[132],"exact":[134],"pathogenesis":[135],"toxicity.":[138],"Interestingly,":[139],"experimental":[141],"suggest":[145],"that":[146,169],"may":[148],"sensitize":[149],"cardiomyocytes":[150],"to":[151,162,171,183,193,203,206],"injuries":[152],"stress":[154],"administration":[156],"anthracyclines.":[158,236],"led":[161],"a":[163],"proposed":[164,200],"novel":[165],"mechanism":[166],"cardiotoxicity":[168],"appears":[170],"be":[172,204],"quite":[173],"anthracycline-associated":[177],"cardiotoxicity.":[178],"does":[180],"not":[181],"seem":[182],"cause":[184],"any":[185],"overt":[186],"ultrastructural":[187],"abnormality;":[188],"it":[189],"does,":[190],"however,":[191],"lead":[192],"myocardial":[194],"dysfunction.":[195],"CONCLUSION:":[196],"Most":[197],"hypotheses":[201],"seems":[202],"related":[205],"activity":[208],"interfering":[212],"with":[213],"ERBB-2":[215],"receptor.":[216],"Indeed,":[217],"setting":[225],"report":[226],"those":[231],"who":[233],"previously":[234],"received":[235]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}